Cargando…

Efficacy of neoadjuvant docetaxel + cisplatin chemo-hormonal therapy versus docetaxel chemo-hormonal therapy in patients with locally advanced prostate cancer with germline DNA damage repair gene alterations

PURPOSE: To assess the efficacy and safety of neoadjuvant docetaxel + cisplatin chemotherapy with androgen deprivation therapy for the treatment of locally advanced prostate cancer (PCa) in patients harboring germline DNA damage repair genes (gDDR) defects. METHODS: We conducted a prospective observ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chi, Chenfei, Liu, Jiazhou, Fan, Liancheng, Zhu, Yinjie, Wang, Yanqing, Sha, Jianjun, Huang, Yiran, Dong, Baijun, Pan, Jiahua, Xue, Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527989/ https://www.ncbi.nlm.nih.gov/pubmed/36199621 http://dx.doi.org/10.1177/17588359221128356

Ejemplares similares

Transcriptomic signature defines two subtypes of locally advanced PCa with distinct neoadjuvant therapy benefits
por: Zhu, Yinjie, et al.
Publicado: (2023)

Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients
por: Bousquet, G, et al.
Publicado: (2011)

Co-treatment by docetaxel and vinblastine breaks down P-glycoprotein mediated chemo-resistance
por: Mohseni, Mahsa, et al.
Publicado: (2016)

Chemo-Enzymatic Synthesis of Ester-Linked Docetaxel-Monosaccharide Conjugates as Water-Soluble Prodrugs
por: Shimoda, Kei, et al.
Publicado: (2011)

Polydopamine-Functionalized CA-(PCL-ran-PLA) Nanoparticles for Target Delivery of Docetaxel and Chemo-photothermal Therapy of Breast Cancer
por: Kong, Na, et al.
Publicado: (2018)

Innovative In Vitro Chemo-Hormonal Drug Therapy for Refractory Thyroid Carcinomas
por: Sung, Tae-Yon, et al.
Publicado: (2012)

Reversal of drug-resistance by noscapine chemo-sensitization in docetaxel resistant triple negative breast cancer
por: Doddapaneni, Ravi, et al.
Publicado: (2017)

Docetaxel/cisplatin Therapy in Myasthenia Gravis with Hypertension/diabetes
por: Qi, Guoyan, et al.
Publicado: (2017)

AB084. Docetaxel therapy for hormone-sensitive prostate cancer—single center result
por: Shao, Qiang, et al.
Publicado: (2015)

Docetaxel–induced syndrome of inappropriate antidiuretic hormone secretion
por: Chaudhuri, Tamojit, et al.
Publicado: (2013)

Assessment of neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil in patients with oral cavity cancer
por: Fu, Jin Ye, et al.
Publicado: (2022)

Abiraterone acetate for chemotherapy-naive metastatic castration-resistant prostate cancer: a single-centre prospective study of efficacy, safety, and prognostic factors
por: Fan, Liancheng, et al.
Publicado: (2018)

Docetaxel treatment in the elderly patient with hormone refractory prostate cancer
por: Sinibaldi, Victoria J
Publicado: (2007)

Early serial circulating tumor DNA sequencing predicts the efficacy of chemohormonal therapy in patients with metastatic hormone-sensitive prostate cancer
por: Du, Xinxing, et al.
Publicado: (2023)

To Chemo or Not to Chemo… That Is the Question
por: Martin, Maria Felisa Eva B., et al.
Publicado: (2023)

Neoadjuvant chemo-immunotherapy for lung cancer: how much is too much?
por: Deboever, Nathaniel, et al.
Publicado: (2022)

Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension (NDLS) versus Conventional Docetaxel as Neoadjuvant and Adjuvant Therapy for Primary Operable Breast Cancer
por: Badiginchala, Revathi, et al.
Publicado: (2023)

Platelet to lymphocyte ratio as an independent prognostic indicator for prostate cancer patients receiving androgen deprivation therapy
por: Wang, Yanqing, et al.
Publicado: (2016)

Co-Adjuvant Therapy Efficacy of Catechin and Procyanidin B2 with Docetaxel on Hormone-Related Cancers In Vitro
por: Núñez-Iglesias, Mª Jesús, et al.
Publicado: (2021)

Combination Effects of Docetaxel and Doxorubicin in Hormone-Refractory Prostate Cancer Cells
por: Tsakalozou, Eleftheria, et al.
Publicado: (2012)

Docetaxel Treatment for Metastatic Hormone-sensitive Prostate Cancer in Daily Practice
por: de Groot, Ietsen, et al.
Publicado: (2021)

Effectiveness of Docetaxel for Metastatic Hormone-sensitive Prostate Cancer in Clinical Practice
por: Lendorf, Maria Elisabeth, et al.
Publicado: (2021)

Pathologic Assessment of Rectal Carcinoma after Neoadjuvant Radio(chemo)therapy: Prognostic Implications
por: Hav, Monirath, et al.
Publicado: (2015)

Early Plasma Circulating Tumor DNA as a Potential Biomarker of Disease Recurrence in Non-metastatic Prostate Cancer
por: Fei, Xiaochen, et al.
Publicado: (2023)

AB140. Efficacy of radical prostatectomy combined with neoadjuvant chemotherapy in the treatment of locally advanced prostate cancer: preliminary experiences from a single center
por: Xue, Wei, et al.
Publicado: (2016)

Pathological response rate in hormone-positive breast cancer patients treated with neoadjuvant FEC and triweekly docetaxel: a case series
por: Kiba, Takayoshi, et al.
Publicado: (2015)

Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin.
por: Hilkens, P. H., et al.
Publicado: (1997)

Safety and Efficacy of Cabazitaxel in the Docetaxel-Treated Patients with Hormone-Refractory Prostate Cancer
por: Calcagno, Fabien, et al.
Publicado: (2012)

Docetaxel, abiraterone, enzalutamide, apalutamide in patients with metastatic hormone-sensitive prostate cancer
por: Talwar, Harkirat Singh
Publicado: (2021)

Outcomes of Older Men Receiving Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer
por: Lage, Daniel E., et al.
Publicado: (2021)

Docetaxel Chemotherapy of Korean Patients with Hormone-refractory Prostate Cancer : Comparative Analysis between 1st-line and 2nd-line Docetaxel
por: Joung, Jae Young, et al.
Publicado: (2008)

Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial
por: Clarke, N W, et al.
Publicado: (2019)

PRKAR2B‐HIF‐1α loop promotes aerobic glycolysis and tumour growth in prostate cancer
por: Xia, Lei, et al.
Publicado: (2020)

Association of mismatch repair status with survival and response to neoadjuvant chemo(radio)therapy in rectal cancer
por: Ye, Shu-Biao, et al.
Publicado: (2020)

Feasibility of classical secondary hormonal therapies prior to docetaxel therapy in Japanese patients with castration-resistant prostate cancer: Multicenter retrospective study
por: Kandori, Shuya, et al.
Publicado: (2016)

“From chemo to chemo”—the temporal paradox of chemotherapy
por: Moskalewicz, Marcin, et al.
Publicado: (2021)

Cost-effectiveness analysis of abiraterone, docetaxel or placebo plus androgen deprivation therapy for hormone-sensitive advanced prostate cancer
por: Aguiar, Pedro Nazareth, et al.
Publicado: (2019)

Effectiveness of Adding Docetaxel to Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer in Korean Real-World Practice
por: Park, Kwonoh, et al.
Publicado: (2023)

Impact of preoperative docetaxel, cisplatin, and 5-fluorouracil (DCF) therapy on degree of malignant esophageal stenosis
por: Yamaguchi, Takahisa, et al.
Publicado: (2023)

Mesoporous Silica Nanoparticles for Dual-Mode Chemo-Sonodynamic Therapy by Low-Energy Ultrasound
por: Wang, Jingjing, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_j557uh9t6h0bncju8or4u3m8f7